#CTLA
Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders.

Read here📄 https://bit.ly/4pw1rVL
November 11, 2026 at 12:00 PM
Launching today on @medliveofficial.bsky.social: “Relapsed Squamous NSCLC: An Emerging Chemo-Free Anti-CTLA-4 Approach.”

Explore this investigational approach live at 12:45 pm ET or on demand afterward through June 11, 2027.

Register: www.medlive.com/aaci/show/26...

#LungCancer #NSCLC
Relapsed Squamous NSCLC: A Chemo-Free Anti-CTLA-4 Approach
Live and on-demand expert session for community oncologists on an investigational anti-CTLA-4 approach in squamous NSCLC after anti-PD-(L)1 progression.
www.medlive.com
November 11, 2026 at 6:55 PM
We've seen CTLA-4 agonists - abatacept 20y in practice
We've seen PD-1 agonists - rosnilimab's phase 2b
What about other immune checkpoint agonists, though?

LAG-3 we know from ICI therapy (relatlimab)
Prepare to see LAG-3 agonist drug development soon

ABSTLB09 #ACR26 RheumNow (on X)
November 11, 2026 at 11:50 AM
🔥Highly Cited Paper
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
✍️by Saud Almawash
Citations: 57✅
Find out more👉 www.mdpi.com/2072-6694/17...
November 10, 2026 at 9:39 AM
Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress
Propper, D. J. & Balkwill, F. R. Harnessing cytokines and chemokines for cancer therapy. Nat. Rev. Clin. Oncol. 19, 237–253 https://doi.org/10.1038/s41571-021-00588-9 (2022). Jeong, G. H. et al. Incidence of capillary leak syndrome as an adverse effect of drugs in cancer patients: a systematic review and meta-analysis. J. Clin. Med. 8, 143 https://doi.org/10.3390/jcm8020143 (2019). Lipson, E. J. & Drake, C. G. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin. Cancer Res. 17, 6958–6962 https://doi.org/10.1158/1078-0432.CCR-11-1595 (2011). Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 https://doi.org/10.1038/nrc3239 (2012). Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 https://doi.org/10.1126/science.aan6733 (2017). Wolchok, J. D. et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 392, 11–22 https://doi.org/10.1056/NEJMoa2407417 (2025). Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 https://doi.org/10.1056/NEJMoa1200694 (2012). Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 https://doi.org/10.1056/NEJMoa1200690 (2012). Primm, K. M., Blackman, E., Zaidi, S. K., Sengupta, R. & Sansbury, B. M. AACR cancer progress...
www.nature.com
November 9, 2026 at 3:00 PM
Control of M. tuberculosis infection requires CD28 to generate lung-homing T cells and CTLA-4 to limit immunopathology from @danbarberphd.bsky.social @nelson-lab.bsky.social @uvaresearch.bsky.social @uvaimmunology.bsky.social: www.mucosalimmunology.org/article/S193...
November 4, 2026 at 5:17 PM
What’s next after chemo-immunotherapy for squamous non-small cell lung cancer?

Join @medliveaboards.bsky.social Nov. 11 at 12:45 pm ET for an expert discussion of an investigational, chemo-free anti-CTLA-4 approach.

Register: www.medlive.com/aaci/show/26...

#NSCLC #LungCancer
November 5, 2026 at 6:01 PM
CTLA-4 checkpoint signalling modulates germinal centre dynamics and antibody avidity during Borrelia burgdorferi infection in mice. bioRxivpreprint
CTLA-4 checkpoint signalling modulates germinal centre dynamics and antibody avidity during Borrelia burgdorferi infection in mice.
Borrelia burgdorferi, the causative agent of Lyme borreliosis, persists in mammalian hosts despite robust activation of innate and adaptive immunity. A hallmark of murine infection is the production of low-avidity antibodies, yet the immunological mechanisms underlying this defective humoral response remain poorly understood. Here, we used single-cell RNA sequencing of draining lymph node cells from Borrelia-infected mice at days 7 and 14 post-infection, comparing transcriptional profiles with those from mice immunised with heat-killed Borrelia or with a potent germinal centre-inducing protein immunisation. Borrelia infection induced a rapid germinal centre response, however, light zone B cells displayed diminished expression of co-stimulatory and T-B cell interaction molecules while maintaining core germinal centre identity markers, suggesting impaired positive selection. T follicular helper cells upregulated multiple inhibitory checkpoint receptor genes, most prominently Ctla4, alongside an active germinal centre engagement programme. Foxp3? regulatory T cells upregulated genes associated with follicular-homing and suppressive function, including those implicated in CTLA-4-mediated trans-endocytosis. To test whether inhibitory signalling contributes to the impaired humoral response, infected mice were treated with anti-CTLA-4 blocking antibody. CTLA-4 blockade significantly increased plasma cell numbers and enhanced both the magnitude and avidity of Borrelia-specific IgG responses, including the induction of complement-fixing IgG2a. These findings reveal that CTLA-4-dependent inhibitory signalling contributes to defective antibody quality during Borrelia infection, identifying a mechanism by which dysregulated T cell responses may facilitate impaired humoral control of a persistent spirochaetal pathogen.
dlvr.it
November 5, 2026 at 5:40 AM
CTLA-4 checkpoint signalling modulates germinal centre dynamics and antibody avidity during Borrelia burgdorferi infection in mice. https://www.biorxiv.org/content/10.64898/2026.10.30.763258v1
November 3, 2026 at 10:18 PM
CTLA-4 checkpoint signalling modulates germinal centre dynamics and antibody avidity during Borrelia burgdorferi infection in mice. https://www.biorxiv.org/content/10.64898/2026.10.30.763258v1
November 3, 2026 at 10:18 PM
CTLA-4 checkpoint signalling modulates germinal centre dynamics and antibody avidity during Borrelia burgdorferi infection in mice. #SingleCell 🧪🧬🖥️
https://www.biorxiv.org/content/10.64898/2026.10.30.763258v1
November 3, 2026 at 11:00 PM
CTLA-4 checkpoint signalling modulates germinal centre dynamics and antibody avidity during Borrelia burgdorferi infection in mice. bioRxivpreprint
CTLA-4 checkpoint signalling modulates germinal centre dynamics and antibody avidity during Borrelia burgdorferi infection in mice.
Borrelia burgdorferi, the causative agent of Lyme borreliosis, persists in mammalian hosts despite robust activation of innate and adaptive immunity. A hallmark of murine infection is the production of low-avidity antibodies, yet the immunological mechanisms underlying this defective humoral response remain poorly understood. Here, we used single-cell RNA sequencing of draining lymph node cells from Borrelia-infected mice at days 7 and 14 post-infection, comparing transcriptional profiles with those from mice immunised with heat-killed Borrelia or with a potent germinal centre-inducing protein immunisation. Borrelia infection induced a rapid germinal centre response, however, light zone B cells displayed diminished expression of co-stimulatory and T-B cell interaction molecules while maintaining core germinal centre identity markers, suggesting impaired positive selection. T follicular helper cells upregulated multiple inhibitory checkpoint receptor genes, most prominently Ctla4, alongside an active germinal centre engagement programme. Foxp3? regulatory T cells upregulated genes associated with follicular-homing and suppressive function, including those implicated in CTLA-4-mediated trans-endocytosis. To test whether inhibitory signalling contributes to the impaired humoral response, infected mice were treated with anti-CTLA-4 blocking antibody. CTLA-4 blockade significantly increased plasma cell numbers and enhanced both the magnitude and avidity of Borrelia-specific IgG responses, including the induction of complement-fixing IgG2a. These findings reveal that CTLA-4-dependent inhibitory signalling contributes to defective antibody quality during Borrelia infection, identifying a mechanism by which dysregulated T cell responses may facilitate impaired humoral control of a persistent spirochaetal pathogen.
dlvr.it
November 3, 2026 at 10:39 PM
Did you know? 🌳 Appraisal

CTLA Guide for Plant Appraisal: cost, income and market (sales comparison) approaches.

Free lessons: arboristpass.com/free #Trees #Arborist #TreeCare
November 1, 2026 at 6:02 PM
Combining anti-PD-1 & anti-CTLA-4 boosts CD8+ T cells in NSCLC brain mets! Study reveals better intracranial control with nivolumab + ipilimumab vs. nivolumab alone. PMID:42414284, Nat Commun 2026, @NatureComms https://doi.org/10.1038/s41467-026-74782-7 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation | Nature Communications
Brain metastases (BrMs) in non-small cell lung cancer (NSCLC) respond poorly to anti-PD-1 monotherapy, but the underlying immune resistance remains incompletely defined. Here we integrate clinical outcome analyses, paired human tissue profiling and syngeneic mouse models to characterize the BrM immune microenvironment. Clinical analyses suggest improved intracranial disease control with nivolumab plus ipilimumab compared with nivolumab alone. Paired human specimens show that BrMs contain fewer cytotoxic T lymphocytes (CTLs) and tertiary lymphoid structures (TLSs) than primary tumors, defining an immune-excluded phenotype. A syngeneic BrM model recapitulates this phenotype and resists anti-PD-1 monotherapy, whereas combined anti-PD-1 and anti-CTLA-4 blockade suppresses tumor growth and prolongs survival. Single-cell RNA sequencing, flow cytometry and immunofluorescence show increased CTL infiltration and effector function after combination therapy. CD8+ T cell depletion abrogates therap
doi.org
November 1, 2026 at 9:00 AM
Can we fix Belatacept’s early rejection problem? This study showed that TIGIT agonism + CTLA-4Ig prolongs graft survival, reduced graft-infiltrating donor-reactive CD8+ T cells, and boosted Tregs in mice. #TXPforAll #Transplantation #Immunology tinyurl.com/wyprxf6a
October 28, 2026 at 12:00 PM
Our most recent publication “Control of M. tuberculosis infection requires CD28 to generate lung-homing T cells and CTLA-4 to limit immunopathology” is out in Mucosal Immunology (open access)! @danbarberphd.bsky.social @mayerbarber.bsky.social @annesperling1.bsky.social @mucosalimmunol.bsky.social
Control of M. tuberculosis infection requires CD28 to generate lung-homing T cells and CTLA-4 to limit immunopathology
Mycobacterium tuberculosis (Mtb)-specific CD4 T cells differentiate into protective lung parenchyma-homing and non-protective intravascular subsets, but the signals that instruct these fates are poorl...
www.mucosalimmunology.org
October 27, 2026 at 7:11 PM
Checkmate -067 study of Yervoy and Opdivo is used in advanced or unresectable first-line treatment already. mRNA vaccine is an adjuvant therapy post surgery. It’s a great discovery but there are options on the table with PD-1 and CTLA-4
October 26, 2026 at 7:37 PM
The phase 3 LITESPARK-012 trial, presented by @drchoueiri.bsky.social, show that adding either the HIF-2α inhibitor belzutifan or the CTLA-4 inhibitor quavonlimab to pembrolizumab and lenvatinib didn’t improve efficacy in previously untreated advanced clear cell renal cell carcinoma. #ESMO26
October 25, 2026 at 7:43 AM
Worth spelling out for trainees: MK-1308A is quavonlimab (anti-CTLA-4) coformulated with pembrolizumab, so one arm tested adding CTLA-4 and the other adding HIF-2α inhibition. Neither beat pembrolizumab plus lenvatinib, which is a lesson that adding a third mechanism isn't automatically additive.
October 21, 2026 at 4:46 PM
Megan Matthews Assumes Presidency of Colorado Trial Lawyers Association for 2026-2027#Megan_Matthews#CTLA#Ogborn_Mihm
Megan Matthews Assumes Presidency of Colorado Trial Lawyers Association for 2026-2027
Ogborn Mihm LLP's partner, Megan Matthews, is appointed as President of the Colorado Trial Lawyers Association for 2026-2027, continuing a legacy of leadership.
third-news.com
October 21, 2026 at 8:28 PM
3/
Let’s start with CTLA-4 in T cells:
mRNA might be high.
But the surface protein?
It's tightly controlled via intracellular trafficking.
October 20, 2026 at 2:15 PM
How does this affect Treg function? We next demonstrated, that Tregs from carriers of the protective rs3087243-A variant express higher storage levels of CTLA-4, and are able to mobilize it faster to the cell surface upon activation.

🧵4/7
October 19, 2026 at 11:10 AM
CTLA-4 is a key immune checkpoint molecule blocking CD80/CD86-mediated costimulation, and particularly important for Treg function.

Common CTLA4 genetic variants are associated with susceptibility to multiple autoimmune diseases, but how they affect human Treg biology has remained unclear.

🧵2/7
October 19, 2026 at 11:10 AM
A key challenge is, that several CTLA4 variants are in strong linkage disequilibrium with each other.

By genotyping a large cohort, we identified individuals with rare haplotypes, through the analysis of which we demonstrated that rs3087243 dictates the level of CTLA-4 expression in T cells.

🧵3/7
October 19, 2026 at 11:10 AM
CTLA4 rs3087243-A–linked haplotype is associated with increased CTLA-4 expression and suppressive function in human regulatory T cells @jimmunol.bsky.social
academic.oup.com/jimmunol/art...
October 17, 2026 at 9:15 PM